Skip to main content

Advertisement

SpringerLink
Log in

Ulcerative Colitis: Update on Medical Management

  • Large Intestine (B Cash, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. Recent advances in diagnosis and treatment have led to significant improvement in managing the disease. Disease monitoring with the use of therapeutic drug monitoring, stool markers, and assessment of mucosal healing have garnered much attention. The recent approval of vedolizumab for treatment of moderate to severe UC has been a welcome addition. Newer biologics, including those targeting the Janus tyrosine kinase (JAK) pathway, are on the horizon to add to the current armamentarium of anti-TNF alpha and anti-integrin therapies. The recent publication of the SCENIC consensus statement on surveillance and management of dysplasia in UC patients supports the use of chromoendoscopy over random biopsies in detecting dysplasia. This review highlights these recent advances along with others that have been made with ulcerative colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78. doi:10.1056/NEJMra0804647.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519–25. doi:10.1007/s10620-012-2371-5.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–13. doi:10.1053/j.gastro.2008.09.012.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26(11):811–7.

    PubMed Central  PubMed  Google Scholar 

  5. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36.

    PubMed  Google Scholar 

  6. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371–85. doi:10.1111/j.1572-0241.2004.40036.x.

    Article  PubMed  Google Scholar 

  8. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–86. doi:10.1053/j.gastro.2006.12.038.

    Article  PubMed  Google Scholar 

  9. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43(1):29–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17. doi:10.1038/nature10209.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Ellinghaus D, Bethune J, Petersen BS, Franke A. The genetics of Crohn's disease and ulcerative colitis—status quo and beyond. Scand J Gastroenterol. 2015;50(1):13–23. doi:10.3109/00365521.2014.990507.

    Article  CAS  PubMed  Google Scholar 

  12. Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24 Suppl 3:2–10. doi:10.1111/j.1365-2036.2006.03052.x.

    Article  CAS  PubMed  Google Scholar 

  13. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24. doi:10.1038/nature11582.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–92. doi:10.1016/j.chom.2014.02.005.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107(9):1399–406. doi:10.1038/ajg.2012.196.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001;96(7):2113–6. doi:10.1111/j.1572-0241.2001.03944.x.

    Article  CAS  PubMed  Google Scholar 

  17. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344(11):808–14. doi:10.1056/NEJM200103153441104.

    Article  CAS  PubMed  Google Scholar 

  18. Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12(5):821–7. doi:10.1016/j.cgh.2013.10.011.

    CAS  Google Scholar 

  19. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, et al. Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39(10):1136–42. doi:10.1111/apt.12706.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Ananthakrishnan AN, Cagan A, Gainer VS, Cai T, Cheng SC, Savova G, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis. 2013;19(9):1921–7. doi:10.1097/MIB.0b013e3182902ad9.

    PubMed Central  PubMed  Google Scholar 

  21. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. 2015;60(2):290–8. doi:10.1007/s10620-014-3350-9.

    Article  CAS  PubMed  Google Scholar 

  22. Ha CY, Newberry RD, Stone CD, Ciorba MA. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8(8):682–87 e1. doi:10.1016/j.cgh.2010.03.022.

    Google Scholar 

  23. Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, et al. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflamm Bowel Dis. 2010;16(7):1227–38. doi:10.1002/ibd.21170.

    Article  PubMed  Google Scholar 

  24. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167–76. doi:10.1038/ajg.2011.410. author reply 77.

    Article  CAS  PubMed  Google Scholar 

  25. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10(5):513–9. doi:10.1016/j.cgh.2011.10.043.

    CAS  Google Scholar 

  26. Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601–16. doi:10.1038/ajg.2011.67.

    Article  CAS  PubMed  Google Scholar 

  27. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433–41. doi:10.1136/gutjnl-2012-304258.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39(10):1095–103. doi:10.1111/apt.12712.

    Article  CAS  PubMed  Google Scholar 

  29. Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015;148(4):740–50 e2. doi:10.1053/j.gastro.2015.01.037.

    Article  CAS  PubMed  Google Scholar 

  30. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21–35. doi:10.1097/01.MIB.0000437495.30052.be.

    Article  PubMed  Google Scholar 

  31. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2009;7(11):1202–9. doi:10.1016/j.cgh.2009.07.016. 9 e1.

    Google Scholar 

  32. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–27. doi:10.1038/ajg.2010.218.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1):CD000478. doi:10.1002/14651858.CD000478.pub2

  34. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55(1):47–53. doi:10.1136/gut.2005.068809.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD006618. doi:10.1002/14651858.CD006618.pub3.

    PubMed  Google Scholar 

  36. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. doi:10.1056/NEJMoa050516. Phase III trials of infliximab therapy in UC.

    Article  CAS  PubMed  Google Scholar 

  37. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65 e1-3. doi:10.1053/j.gastro.2011.10.032. Phase III trial of adalimumab therapy in UC.

    Article  CAS  PubMed  Google Scholar 

  38. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95; quiz e14-5. doi:10.1053/j.gastro.2013.05.048. Phase III trial of golimumab therapy in UC.

  39. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e1. doi:10.1053/j.gastro.2013.06.010.

    Article  CAS  PubMed  Google Scholar 

  40. Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400 e3. doi:10.1053/j.gastro.2013.10.052. Combination therapy with inflximab and azathioprine in UC.

    Article  CAS  PubMed  Google Scholar 

  41. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383–95. doi:10.1056/NEJMoa0904492.

    Article  CAS  PubMed  Google Scholar 

  42. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. doi:10.1056/NEJMoa1215734. Phase III trial of vedolizumab therapy in UC.

    Article  CAS  PubMed  Google Scholar 

  43. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120(6):1323–9.

    Article  PubMed  Google Scholar 

  44. Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000;119(4):903–8.

    Article  CAS  PubMed  Google Scholar 

  45. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11.

    Article  PubMed  Google Scholar 

  46. Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13(2):330–35 e1. doi:10.1016/j.cgh.2014.07.041.

    CAS  Google Scholar 

  47. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn's Colitis. 2012;6(10):991–1030. doi:10.1016/j.crohns.2012.09.002. Most recent ECCO guidelines for management of UC.

    Article  Google Scholar 

  48. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24. doi:10.1056/NEJMoa1112168. Results of phase II study of tofacitinib for UC.

    Article  CAS  PubMed  Google Scholar 

  49. Panes J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015;15(1):14. doi:10.1186/s12876-015-0239-9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–18. doi:10.1016/S0140-6736(14)60661-9. Results of phase II study of etrolizumab for UC.

    Article  CAS  PubMed  Google Scholar 

  51. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohn's Colitis. 2014;8(12):1569–81. doi:10.1016/j.crohns.2014.08.006. A meta-analysis of studies examining use of FMT for IBD.

    Article  Google Scholar 

  52. Moayyedi P, Marshall JK, Yuan Y, Hunt R. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol Hepatol. 2014;28(2):66–8.

    PubMed Central  PubMed  Google Scholar 

  53. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015. doi:10.1053/j.gastro.2015.04.001.

    PubMed Central  Google Scholar 

  54. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065–71. doi:10.1038/ajg.2014.133.

    Article  PubMed  Google Scholar 

  55. Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014;147(5):981–9. doi:10.1053/j.gastro.2014.08.044.

    Article  CAS  PubMed  Google Scholar 

  56. Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;6:109. doi:10.12703/P6-109.

    PubMed Central  PubMed  Google Scholar 

  57. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068–75. doi:10.1136/gut.2010.226548.

    Article  CAS  PubMed  Google Scholar 

  58. Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108(1):90–8. doi:10.1038/ajg.2012.340.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol. 2015;8(2):66–82. doi:10.1177/1756283X14558193.

    Article  CAS  Google Scholar 

  60. Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the toronto consensus. Gastroenterology. 2015;148(5):1035–58 e3. doi:10.1053/j.gastro.2015.03.001. Consensus guidelines with helpful algorithms and goals for outpatient UC therapy.

    Article  PubMed  Google Scholar 

  61. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(6):483–89 e3. doi:10.1016/j.cgh.2010.12.028.

    Google Scholar 

  62. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–201. doi:10.1053/j.gastro.2011.06.054.

    Article  CAS  PubMed  Google Scholar 

  63. Laharie D, Filippi J, Roblin X, Nancey S, Chevaux JB, Hebuterne X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37(10):998–1004. doi:10.1111/apt.12289.

    Article  CAS  PubMed  Google Scholar 

  64. Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412–22. doi:10.1053/j.gastro.2007.05.051.

    Article  PubMed  Google Scholar 

  65. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res J Lab Clin Med. 2012;159(4):313–25. doi:10.1016/j.trsl.2012.01.001.

    Article  CAS  Google Scholar 

  66. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332–41. doi:10.1097/MIB.0b013e3182810066.

    Article  PubMed  Google Scholar 

  67. Afif W, Loftus Jr EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9. doi:10.1038/ajg.2010.9.

    Article  CAS  PubMed  Google Scholar 

  68. Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109(8):1250–6. doi:10.1038/ajg.2014.146.

    Article  CAS  PubMed  Google Scholar 

  69. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–81 e1. doi:10.1053/j.gastro.2012.04.016. quiz e13-4.

    Article  PubMed  Google Scholar 

  70. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):645–59. doi:10.1111/apt.12651.

    Article  CAS  PubMed  Google Scholar 

  71. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25. doi:10.1056/NEJMra1102942.

    Article  CAS  PubMed  Google Scholar 

  72. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23. doi:10.1038/ajg.2009.727. quiz 24.

    Article  PubMed  Google Scholar 

  73. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74. doi:10.1053/j.gastro.2009.12.035. 74 e1-4; quiz e12-3.

    Article  PubMed  Google Scholar 

  74. Shah SA, Rubin DT, Farraye FA. Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2014;16(9):407. doi:10.1007/s11894-014-0407-z. In depth review on use of chromoendoscopy in IBD.

    Article  PubMed  Google Scholar 

  75. Kaminski MF, Hassan C, Bisschops R, Pohl J, Pellise M, Dekker E, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2014;46(5):435–49. doi:10.1055/s-0034-1365348. ESGE review of advanced imaging for dysplasia/cancer detection in a variety of setting including IBD surveillance for which chromoendoscopy strongly endorsed.

    Article  PubMed  Google Scholar 

  76. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334–9.

    Article  PubMed  Google Scholar 

  77. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65(7):998–1004. doi:10.1016/j.gie.2006.09.025.

    Article  PubMed  Google Scholar 

  78. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148(3):639–51 e28. doi:10.1053/j.gastro.2015.01.031. Most up-to-date ASGE guidelines on surveillance and management of dysplasia in IBD with support for chromoendoscopy.

    Article  PubMed  Google Scholar 

  79. Committee ASoP, Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81(5):1101–21 e13. doi:10.1016/j.gie.2014.10.030.

    Article  Google Scholar 

  80. van den Broek FJ, Stokkers PC, Reitsma JB, Boltjes RP, Ponsioen CY, Fockens P, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. 2014;109(5):715–22. doi:10.1038/ajg.2011.93.

    Article  PubMed  Google Scholar 

  81. Subramanian V, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(3):304–12. doi:10.1111/j.1365-2036.2010.04525.x.

    Article  CAS  PubMed  Google Scholar 

  82. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124(4):880–8. doi:10.1053/gast.2003.50146.

    Article  PubMed  Google Scholar 

  83. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Wu L, Li P, Wu J, Cao Y, Gao F. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Color Dis Off J Assoc Coloproctol G B Irel. 2012;14(4):416–20. doi:10.1111/j.1463-1318.2010.02505.x.

    CAS  Google Scholar 

  85. Konijeti GG, Shrime MG, Ananthakrishnan AN, Chan AT. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. 2014;79(3):455–65. doi:10.1016/j.gie.2013.10.026.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Efthymiou M, Allen PB, Taylor AC, Desmond PV, Jayasakera C, De Cruz P, et al. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2132–8. doi:10.1097/MIB.0b013e31829637b9.

    Article  PubMed  Google Scholar 

  87. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89. doi:10.1136/gut.2009.179804.

    Article  PubMed  Google Scholar 

  88. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn's Colitis. 2013;7(12):982–1018. doi:10.1016/j.crohns.2013.09.016.

    Article  Google Scholar 

  89. Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. Gastroenterology. 2015;148(3):462–7. doi:10.1053/j.gastro.2015.01.029.

    Article  PubMed  Google Scholar 

  90. Kiesslich R, Neurath MF. Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut. 2004;53(2):165–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103(9):2342–9. doi:10.1111/j.1572-0241.2008.01934.x.

    Article  PubMed  Google Scholar 

  92. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, Fidder HH, Siersema PD, Dekker E, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015. doi:10.1038/ajg.2015.63.

    PubMed  Google Scholar 

  93. Kiesslich R, Neurath MF. Chromoendoscopy in inflammatory bowel disease. Gastroenterol Clin N Am. 2012;41(2):291–302. doi:10.1016/j.gtc.2012.01.016. Concise review of chromoendoscopy in UC with description of method.

    Article  Google Scholar 

  94. Soetikno R, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013;144(7):1349–52, 52 e1-6. doi:10.1053/j.gastro.2013.04.008. Concise review of chromoendoscopy with practical information on incorporating into practice with link to video.

  95. Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM, Sandborn WJ, et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(5):546–54. doi:10.1111/apt.12218.

    Article  CAS  PubMed  Google Scholar 

  96. Manolakis CS, Cash BD. Health maintenance and inflammatory bowel disease. Curr Gastroenterol Rep. 2014;16(10):402. doi:10.1007/s11894-014-0402-4.

    Article  PubMed  Google Scholar 

  97. Sinclair JA, Wasan SK, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin N Am. 2012;41(2):325–37. doi:10.1016/j.gtc.2012.01.006. A summary of health maintenance issues for the gastroenterologist and primary care physician.

    Article  Google Scholar 

  98. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585–95. doi:10.1038/nrgastro.2013.117.

    Article  CAS  PubMed  Google Scholar 

  99. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10(6):597–605.

    Article  PubMed  Google Scholar 

  100. Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep. 2000;2(2):87–8.

    Article  CAS  PubMed  Google Scholar 

  101. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451–71. doi:10.1016/j.berh.2006.03.010.

    Article  PubMed  Google Scholar 

  102. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26(3):265–73. doi:10.1016/j.clindermatol.2007.10.018.

    Article  PubMed  Google Scholar 

  103. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382(9904):1587–99. doi:10.1016/S0140-6736(13)60096-3.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Heba N. Iskandar reports research support/grants from Abbvie, Salix, and UCB, outside the submitted work.

Francis A. Farraye reports personal fees from Abbvie, personal fees from Janssen, personal fees from Salix, outside the submitted work.

Tanvi Dhere declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Digestive Diseases, Emory University, 1365 Clifton Rd. NE, Building B, Suite 1200, Atlanta, GA, 30322, USA

    Heba N. Iskandar & Tanvi Dhere

  2. Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, 85 East Concord Street, Boston, MA, 02118, USA

    Francis A. Farraye

Authors
  1. Heba N. Iskandar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanvi Dhere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francis A. Farraye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heba N. Iskandar.

Additional information

This article is part of the Topical Collection on Large Intestine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iskandar, H.N., Dhere, T. & Farraye, F.A. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep 17, 44 (2015). https://doi.org/10.1007/s11894-015-0466-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-015-0466-9

Keywords

Search

Navigation